First human test for promising new cancer pill
NCT ID NCT06223542
Summary
This is an early safety study for a new drug called TAK-243 in adults with advanced solid tumors or lymphoma. The main goal is to find the safest dose and understand the side effects. Researchers will give the drug to about 95 patients and closely monitor how their bodies handle it.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INDOLENT NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Cancer Institute Developmental Therapeutics Clinic
RECRUITINGBethesda, Maryland, 20892, United States
Contact
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.